- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07948629
Stressor-Focused Therapy for Emotional Processing in Adjustment Disorder (STEP)
STEP - Stressor-focused Therapy for Emotional Processing in ICD-11 Adjustment Disorder: A Randomised Waitlist-Controlled Trial
This randomized controlled trial evaluates the efficacy of STEP, a brief 12-session psychotherapy for adults with ICD-11 Adjustment Disorder (AjD). STEP is a manualized, CBT-based, event-focused intervention designed to reduce Adjustment Disorder symptoms and support adaptive emotional processing and coping. Participants in the waitlist control group will receive STEP after the 12-week waiting period. Outcomes will be assessed at baseline, post-treatment, and at a 3-month follow-up. The primary outcome is Adjustment Disorder symptom severity. Secondary outcomes include perceived stress, depression, anxiety, well-being, and experiential avoidance.
Study Overview
Detailed Description
Adjustment disorder (AjD) is characterised in ICD-11 by two core symptom clusters: preoccupation with the stressor and failure to adapt. Although adjustment disorder is frequently diagnosed in clinical practice, evidence for disorder-specific psychological treatments based on the ICD-11 conceptualisation remains limited.
STEP (Stressor-focused Therapy for Emotional Processing) was developed to address these core symptoms through a structured, event-focused cognitive-behavioural approach. The treatment is based on the conceptualisation of adjustment disorder as a stress-response syndrome, in which persistent preoccupation with a stressful life event and avoidance of associated memories, thoughts, and emotions may contribute to symptom maintenance.
Drawing on established cognitive-behavioural and trauma-focused treatment principles, STEP integrates psychoeducation, individual case formulation, emotional awareness and regulation, event-focused imaginal exposure, cognitive restructuring, resource activation, and adaptive coping strategies. A central component is the guided emotional processing of distressing life events and emotionally salient moments associated with the stressor. The intervention aims to reduce maladaptive avoidance and preoccupation, facilitate emotional processing, and support adaptation to changed life circumstances.
This randomised waitlist-controlled trial evaluates the efficacy of STEP in adults diagnosed with ICD-11 adjustment disorder. The primary hypothesis is that participants receiving STEP will demonstrate greater reductions in adjustment disorder symptoms than participants assigned to the waitlist condition. Secondary objectives include examining changes in psychological distress, experiential avoidance, and subjective well-being, as well as evaluating treatment feasibility and acceptability.
The study is expected to contribute to the development of targeted, evidence-based psychotherapeutic interventions for adjustment disorder.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Rahel Bachem, Prof. Dr.
- Phone Number: +41 58 257 35 26
- Email: rahel.bachem@ost.ch
Study Locations
-
-
Canton of St. Gallen
-
Sankt Gallen, Canton of St. Gallen, Switzerland, 9001
- Competence Center for Mental Health; Eastern Switzerland University of Applied Sciences
-
Contact:
- Rahel Bachem, Prof. Dr.
- Phone Number: +41 58 257 35 26
- Email: rahel.bachem@ost.ch
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥ 18 years
- Diagnosis of ICD-11 Adjustment Disorder confirmed via structured clinical interview using the IADQ diagnostic algorithm
- Presence of a clearly identifiable psychosocial stressor 2 weeks to 2 years before participation
- Sufficient German language proficiency to participate in psychotherapy and complete study assessments
- Capacity to provide written informed consent
Exclusion Criteria:
- Current PTSD or CPTSD meeting ICD-11 diagnostic criteria following a Criterion A traumatic event
- Current prolonged grief disorder meeting ICD-11 diagnostic criteria
- Lifetime history of bipolar disorder or psychotic disorder, including schizophrenia spectrum disorders
- Severe depressive or anxiety symptoms clearly predating the identified stressor and judged to better account for the current clinical presentation
- Another severe mental disorder that would interfere with participation in psychotherapy or better explain the presenting symptoms
- Acute suicidality requiring immediate crisis intervention
- Ongoing psychotherapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: STEP Intervention Group
Participants assigned to the intervention group receive 12 weekly sessions of the STEP psychotherapy intervention after completion of the baseline assessment. |
STEP is a brief, manualized, 12-session CBT-based psychotherapy specifically developed for ICD-11 Adjustment Disorder (AjD). It follows a staged, event-focused approach targeting the core symptom clusters of preoccupation and failure to adapt. Treatment components include psychoeducation and individualized case conceptualization, emotional awareness and regulation skills, stressor-focused imaginal exposure and emotional processing, cognitive and emotional reprocessing of stressor-related meanings, strengthening of personal resources and adaptive coping strategies, and relapse prevention. |
|
Other: Waitlist Control Group
Participants assigned to the waitlist control group do not receive the STEP intervention during the 12-week waiting period. After completion of the waiting period, participants receive the STEP intervention. |
STEP is a brief, manualized, 12-session CBT-based psychotherapy specifically developed for ICD-11 Adjustment Disorder (AjD). It follows a staged, event-focused approach targeting the core symptom clusters of preoccupation and failure to adapt. Treatment components include psychoeducation and individualized case conceptualization, emotional awareness and regulation skills, stressor-focused imaginal exposure and emotional processing, cognitive and emotional reprocessing of stressor-related meanings, strengthening of personal resources and adaptive coping strategies, and relapse prevention. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adjustment Disorder Symptom Severity at Post-Treatment
Time Frame: Week 12-14 after baseline (T1; post-treatment in the immediate intervention group and post-waiting period in the control group)
|
Adjustment disorder symptom severity is assessed using the International Adjustment Disorder Questionnaire (IADQ). The primary outcome is the sum of six symptom items (Items 1-6), covering preoccupation with the stressor and failure to adapt. Each item is rated from 0 to 4, resulting in a total score ranging from 0 to 24, with higher scores indicating greater symptom severity. Scores at T1 will be compared between groups, adjusting for baseline scores. |
Week 12-14 after baseline (T1; post-treatment in the immediate intervention group and post-waiting period in the control group)
|
|
Depressive Symptom Severity
Time Frame: Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).
|
Assessed using the International Depression Questionnaire (IDQ), measuring depressive symptoms according to ICD-11. |
Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Anxiety Symptom Severity
Time Frame: Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).
|
Assessed using the International Anxiety Questionnaire (IAQ), measuring symptoms of generalized anxiety according to ICD-11. |
Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).
|
|
Perceived Stress
Time Frame: Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).
|
Assessed using the 10-item Perceived Stress Scale (PSS-10), measuring the perceived level of stress. |
Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).
|
|
Subjective Well-Being
Time Frame: Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).
|
Assessed using the World Health Organization-Five Well-Being Index (WHO-5), measuring subjective psychological well-being. |
Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).
|
|
Experiential Avoidance
Time Frame: Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).
|
Assessed using the Brief Experiential Avoidance Questionnaire (BEAQ), measuring the tendency to avoid unwanted internal experiences. |
Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).
|
|
Adjustment Disorder Diagnostic Status
Time Frame: Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).
|
Assessed through a structured clinical interview evaluating the presence or absence of ICD-11 adjustment disorder and diagnostic remission. |
Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).
|
|
Treatment Credibility and Expectancy
Time Frame: Immediately after STEP Session 1
|
Assessed using the Credibility/Expectancy Questionnaire (CEQ), measuring treatment credibility and expected improvement. |
Immediately after STEP Session 1
|
|
Treatment Acceptability and Feasibility
Time Frame: Immediately after completion of the 12-session STEP treatment
|
Assessed using the Treatment Feedback and Adherence questionnaire (TFA), evaluating participants' experiences with STEP. |
Immediately after completion of the 12-session STEP treatment
|
|
Event-Focused Repetitive Thoughts
Time Frame: Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).
|
Assessed using the Event-focused Repetitive Thoughts Questionnaire (ERTQ), measuring repetitive thoughts related to stressful life events. |
Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Bachem R, Maercker A. Self-help interventions for adjustment disorder problems: a randomized waiting-list controlled study in a sample of burglary victims. Cogn Behav Ther. 2016 Sep;45(5):397-413. doi: 10.1080/16506073.2016.1191083. Epub 2016 Jun 14.
- Levin Y, Bachem R, Hyland P, Karatzias T, Shevlin M, Ben-Ezra M, Maercker A. Validation of the International Adjustment Disorder Questionnaire in Israel and Switzerland. Clin Psychol Psychother. 2022 Jul;29(4):1321-1330. doi: 10.1002/cpp.2710. Epub 2022 Jan 20.
- Bachem R, Casey P. Adjustment disorder: A diagnosis whose time has come. J Affect Disord. 2018 Feb;227:243-253. doi: 10.1016/j.jad.2017.10.034. Epub 2017 Oct 23.
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- STEP_PILOTSTUDY
- PT0041_222855 (Other Grant/Funding Number: Swiss National Science Foundation - SNSF)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
A fully anonymized individual participant dataset will be made available in a publicly accessible scientific repository (e.g., OSF) following publication of the primary study results. All direct identifiers will be removed, and indirect identifiers will be minimized to prevent re-identification. No identifiable or coded participant data will be shared.
IPD Sharing Time Frame
The anonymized individual participant dataset will become publicly available following publication of the primary study results. The dataset will remain accessible for as long as it is maintained in the selected public scientific data repository.
IPD Sharing Access Criteria
The fully anonymized dataset will be publicly accessible to researchers and other interested users through an open scientific data repository, such as the Open Science Framework (OSF), without an individual access request. The shared dataset will contain numerical questionnaire data and broadly categorized demographic information. Free-text descriptions, exact age, geographical information, direct identifiers, and coded participant data will not be made publicly available. A data dictionary will accompany the dataset.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.